The recommendation of the Standing Committee for Vaccinations: According to new studies with Pfizer there would be a lower risk of myocarditis. France, Canada, Finland and Sweden also limit Moderna
For the under 30 and pregnant women (regardless of age) only the Pfizer / BioNTech because, according to some studies, it would involve a lower risk of heart inflammation than that of Moderna. The recommendation comes from Stiko, the German Immunization Committee, and it also applies to those who received different vaccines for the first few doses. For now, this is just an opinion, which will have to be evaluated by other pools of experts.
The (rare) risks of myocarditis
Motivating its position, Stiko cited new data from the Paul Ehrlich Institute, the German vaccine authority, and international studies. But Germany is not the first European country to ask for a limitation on the use of the Moderna vaccine. In recent days the French Public Health Authority stated that in the under 30s the use of Comirnaty (Pfizer) is preferable to Spikevax (Moderna) and similar recommendations have been issued in Canada, Finland and Sweden. The French Haute Autorit de Sant (Has), which does not have the power to grant or prohibit drug licenses but acts as an advisor to the Government, cited very rare risks of myocarditis
, an inflammation of the muscle tissue of the heart, found mainly in males.
Modern recommended for over 30s
In the population under 30, the odds of contracting the disease seem to be around five times lower with the Comirnaty vaccine versus Spikevax wrote the Has in an opinion published Monday. The Authority explained that the indication applies to all three doses (regardless of whether different vaccines have been previously received) and that it will remain valid until new scientific data on the subject are available. On the other hand, for people over 30 years old, the Has explicitly recommended the use of the Moderna vaccine, explaining that its effectiveness is slightly higher than Pfizer’s.
The benefits outweigh the risks
In October, the EMA (European Medicines Agency) approved the third dose with Moderna for the entire population over 18, at least six months after the second injection. The Agency has long confirmed the existence of a possible link between rare cardiac inflammation and mRna vaccines, but, according to the EMA, the benefits of both in preventing Covid outweigh the risks: a position shared by Fda American (Food and Drug Administration) and byWorld Health Organization.
Vaccination for under 12s
In the last few hours, Moderna’s authorization request for vaccination from 6 to 11 years
and the evaluation immediately started. For a decision it will be necessary to wait about two months, unless – the body explained – further clarifications are needed from the manufacturing company. EMA is also looking at the data from Pfizer, which has applied for authorization for its own vaccine in 5-11 year olds: this review could be completed in December. Moderna’s Spikevax vaccine currently authorized in Europe for ages 12 and up; in the United States, however, it can only be used in over 18s.
November 10, 2021 (change November 10, 2021 | 17:13)
© REPRODUCTION RESERVED
#Germany #Pfizer #dose #pregnant #women